AstraZeneca's Research Grant System Expands in Japan For Academics Hungry For Industry Collaborations
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Unlike the handful of global pharmaceutical competitors that closed up research operations in Japan a few years ago, AstraZeneca PLC has never had research facilities in Japan to close. But now, the company is trying to tap into academia to find useful technologies by awarding small grants to researchers, a program so successful that the company has launched similar efforts in South Korea and Russia
You may also be interested in...
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay
AZ Continues To Buy Pipeline With $100M Rigel Deal
Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.
Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 2 of 2)
Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company operates in Japan, the United States, South Korea, Taiwan, Singapore and China. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News' Japan bureau to give his perspective on the how the International Conference on Harmonization Good Clinical Practices agreements will affect Japan and other Asian countries. Japan, for the first time is beginning to accept clinical data from China and Koreain accordance with the ICH Regional Harmonization Initiative.